P2630 - Longitudinal Study of Sexual Dysfunction in Men and Women With Inflammatory Bowel Disease Initiating Biologic or Small Molecule Therapy

Gabriel Castillo, MD¹, William Beaty, MD¹, Olivia R. Delau, MS², Keith Sultan, MD, FACG³, Dana J. Lukin, MD⁴, Adam S.. Faye, MD¹, Sonia Friedman, MD⁵, Jordan Axelrad, MD, MPH^1
1NYU Grossman School of Medicine, New York, NY; ²NYU Langone Health Inflammatory Bowel Disease Center, Cortlandt Manor, NY; ³Northwell Health, Manhasset, NY; ⁴Jill Roberts Center for Inflammatory Bowel Disease, New York Presbyterian Hospital-Weill Cornell Medicine, New York, NY; ⁵Tufts University School of Medicine, Boston, MA

Introduction: Patients with inflammatory bowel disease (IBD) have increased rates of sexual dysfunction (SD). This study investigated SD longitudinally in patients initiating a biologic or small molecule therapy.

Methods: Patients with Crohn’s disease (CD) or ulcerative colitis (UC) starting biologic or small molecule therapy were surveyed at induction, 2 months, and 6 months. Surveys included the IBD-Female and Male Sexual Dysfunction Scales (FSDS and MSDS), PROMIS Sexual Function and Satisfaction Brief Profile, Short IBD Questionnaire (SIBDQ), Patient Health Questionnaire-9 (PHQ-9), and IBD Disability Index (IBDDI). Clinical disease activity scales included the Harvey-Bradshaw Index (HBI), simple clinical colitis activity index (SCCAI), and partial Mayo (pMayo) score. Endoscopic scores and biomarkers of inflammation were collected. To assess changes in SD, disease activity, and psychosocial metrics, Wilcoxon Signed-Rank tests were performed to compare scores at each study timepoint

Results: A total of 170 patients (89 males and 81 females) completed surveys at induction, 133 at 2 months, and 116 at 6 months. The median age was 31.5 years (IQR 18-30), 59% had CD, and 41% had UC. At induction, the median HBI score was 5.5 (4-7), SCCAI 6 (4-8), and pMayo 4 (2-5), for patients with CD and UC, respectively. At induction, the median MSDS score was 6 (3-13) out of 40, and the median FSDS was 13 (7-27) out of 60, corresponding to a moderate degree of SD. SD Scores (MSDS, FSDS, and PROMIS scores) correlated with the SCCAI, pMayo and HBI (p < 0.05) across study time points, but did not consistently correlate with biomarkers of inflammation or endoscopic indices (Figure 1). SD scores also correlated with SIBDQ, and PHQ-9 (p < 0.05) across study time points. The PROMIS subdomains assessing sexual interest, satisfaction, and orgasm also correlated with clinical disease activity indices and psychosocial scales (p < 0.05). SD scores, SIBDQ, and IBDDI significantly improved in patients with a therapeutic response; however, this was not observed in therapy non-responders (p < 0.001) (Table 1). A multivariate analysis revealed that the SIBDQ had the strongest influence on SD.

Discussion: SD was highly prevalent in this cohort of IBD patients, and consistently associated with clinical disease activity and quality of life measures. These results suggest that SD can improve with biologic therapy. Improvement may be driven by changes in clinical disease activity and psychosocial factors.



Disclosures:


Gabriel Castillo, MD¹, William Beaty, MD¹, Olivia R. Delau, MS², Keith Sultan, MD, FACG³, Dana J. Lukin, MD⁴, Adam S.. Faye, MD¹, Sonia Friedman, MD⁵, Jordan Axelrad, MD, MPH¹. P2630 - Longitudinal Study of Sexual Dysfunction in Men and Women With Inflammatory Bowel Disease Initiating Biologic or Small Molecule Therapy, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.